Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
Eli Lilly and Company
City of Hope Medical Center
National Cancer Institute (NCI)
Imunon
AstraZeneca
AstraZeneca
AstraZeneca
NRG Oncology
OHSU Knight Cancer Institute
National Cancer Institute (NCI)
AstraZeneca
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
University Health Network, Toronto
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Akeso
AbbVie
Merck Sharp & Dohme LLC
University of Washington
Toray Industries, Inc
GlaxoSmithKline
Danish Gynecological Cancer Group
CanariaBio Inc.
Merck Sharp & Dohme LLC
AGO Research GmbH
University College, London
Mercy Medical Center
Huazhong University of Science and Technology
NETRIS Pharma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Huazhong University of Science and Technology